L & S Advisors Inc Sells 1,734 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

L & S Advisors Inc decreased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,065 shares of the medical equipment provider’s stock after selling 1,734 shares during the period. L & S Advisors Inc’s holdings in Intuitive Surgical were worth $6,702,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ISRG. Vanguard Group Inc. grew its position in shares of Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after buying an additional 493,126 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Intuitive Surgical by 1.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after purchasing an additional 272,741 shares in the last quarter. Capital World Investors raised its holdings in Intuitive Surgical by 1.0% during the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after acquiring an additional 73,634 shares during the period. Edgewood Management LLC boosted its position in shares of Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after acquiring an additional 374,667 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in Intuitive Surgical by 4.6% during the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after buying an additional 198,483 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 0.3 %

Shares of NASDAQ:ISRG opened at $491.39 on Tuesday. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $496.18. The company has a 50 day moving average of $464.67 and a 200-day moving average of $422.79. The firm has a market cap of $174.30 billion, a P/E ratio of 88.70, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the firm posted $1.18 earnings per share. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. Equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on ISRG shares. JPMorgan Chase & Co. lifted their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Morgan Stanley lifted their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Citigroup boosted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Barclays boosted their price target on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $446.45.

Insiders Place Their Bets

In related news, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the transaction, the executive vice president now directly owns 298 shares in the company, valued at $136,522.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Myriam Curet sold 2,818 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at $136,522.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $438.60, for a total transaction of $619,741.80. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,414,931.60. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 in the last three months. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.